Nov 18 (Reuters) - Biogen Idec Inc:
* Genentech and Biogen Idec receive a complete response from the FDA for
Rituxan for chronic lymphocytic leukemia
* Says it and Genentech will continue final label discussions with the FDA
* Says FDA has not requested any new data to complete its review of these
applications
* Says committed to making Rituxan in combination with FC an FDA-approved
option for people with CLL
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Genentech and Biogen Idec receive a complete response from the FDA for
Rituxan for chronic lymphocytic leukemia
* Says it and Genentech will continue final label discussions with the FDA
* Says FDA has not requested any new data to complete its review of these
applications
* Says committed to making Rituxan in combination with FC an FDA-approved
option for people with CLL
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
